Inogen

Inogen generated total revenue of $85.1 million in the first quarter of 2026, beating analysts’ expectations, while diluted GAAP earnings per share were -$0.30, missing estimates. Net loss widened to $8.3 million and adjusted EBITDA fell to -$1.4 million, driven by higher operating expenses and one‑time restructuring and shareholder‑retention charges. International growth (+17.8% to $37.7 million) accounted for 44.3% of revenue, while U.S. revenue declined; adjusted gross margin improved slightly to 44.7%. Management continues to prioritize higher R&D spending and product launches but expects ongoing profitability challenges and forecasts negative EPS for upcoming quarters. » More on de.investing.com

Inogen reported Q1 2026 revenue of $85.1 million, topping the estimate of $82.35 million; the adjusted gross margin rose to 44.7%, indicating operational efficiency. Earnings per share were -$0.30, missing the forecast of -$0.29, and the stock fell in after-hours trading. Strong international growth (+18% y/y) offset declines in the U.S. market, while higher R&D and operating expenses weighed on profitability. Management remains focused on international expansion and product launches but maintains a cautious outlook with continued negative EPS guidance. » More on de.investing.com

Inogen reported Q1 2026 revenue of $85.1 million, beating expectations by 3.34%, but posted diluted earnings per share of -$0.30. International growth supported the results (+17.8% to $37.7 million), while U.S. revenue fell 4.8% to $34.7 million and U.S. rental revenue declined. Operating expenses and R&D increased, the operating loss widened to -$9.3 million and net loss to -$8.3 million; adjusted EBITDA remained negative. Management highlighted new products such as the CPAP mask "Aurora" and is targeting margin improvements, but expects profitability to improve only in subsequent quarters. » More on de.investing.com